Loading...
•
Sep 30, 2021
Supernus Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021.
Key Takeaways
Supernus Pharmaceuticals reported Q3 2021 total revenues of $148.5 million, a 4% decrease compared to $155.1 million in Q3 2020. Net earnings were $21.6 million, or $0.40 per diluted share, compared to $40.0 million, or $0.74 per diluted share, for the same period in 2020.
Total revenues for Q3 2021 were $148.5 million, a 4% decrease compared to Q3 2020.
Operating earnings for Q3 2021 were $32.6 million, compared to $56.1 million for the same period in 2020.
Net earnings for Q3 2021 were $21.6 million, compared to $40.0 million for the same period in 2020.
The company expects to resubmit the SPN-830 NDA to the FDA in November 2021.
Revenue by Segment
Forward Guidance
The Company increases its financial guidance for operating earnings, lowers its financial guidance for total combined R&D and SG&A expenses, and lowers the top end of its financial guidance range for total revenues for full year 2021.
Positive Outlook
- Total revenues are expected to be between $550 million and $570 million.
- Combined R&D and SG&A expenses are expected to be between $370 million and $400 million.
- Operating earnings are expected to be between $90 million and $95 million.
- Amortization of intangible assets is expected to be $24 million.
- Effective tax rate is expected to be between 28% and 31%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...